Recent work that illustrated the importance of EZH2 and H3K27me3 reprogramming in LSC survival was able to show the effectiveness of combining an EZH2 inhibitor with nilotinib on Ph+CD45+CD34+CD38− cells from the BM of NSG xenografted mice, being the first published study of CML CP to illustrate efficacy in such a primitive cell population in vivo [10]. This evidence concerns the gene CD38 and chronic myelogenous leukemia, BCR-ABL1 positive.